Thalassemia

Key Points

• Thalassemia is a hereditary hemoglobin-gene disorder that decreases effective erythropoiesis and oxygen-carrying capacity.
• Clinical severity varies widely, from asymptomatic carrier patterns to transfusion-dependent severe anemia.
• Common manifestations include fatigue, weakness, pallor, and dyspnea; severe disease can include splenomegaly, jaundice, and bone deformities.
• Diagnostic confirmation uses CBC patterning, hemoglobin electrophoresis, peripheral smear, and genetic testing.
• Ongoing transfusion support can lead to iron overload, requiring long-term iron-chelation surveillance and therapy.

Pathophysiology

Thalassemia is a group of inherited hemoglobinopathies caused by defects in globin-chain production. Reduced globin synthesis lowers functional hemoglobin output, weakens oxygen transport, and drives chronic anemia of variable severity.

Normal adult hemoglobin contains two alpha and two beta chains. In thalassemia, reduced chain production disrupts this balance and increases ineffective erythropoiesis.

Classification

• Alpha-thalassemia: Deletion of one or more alpha-globin genes; severe forms can require early-childhood transfusion support and may carry high perinatal risk.
• Beta-thalassemia: Deletion of one or more beta-globin genes with variable anemia burden and transfusion needs.
• Carrier versus severe disease spectrum: Some patients remain minimally symptomatic carriers, while others require regular transfusions and close lifelong monitoring.

Nursing Assessment

NCLEX Focus

Prioritize anemia severity, transfusion burden, and iron-overload surveillance while monitoring psychosocial and family-planning needs.

• Assess fatigue, exertional dyspnea, weakness, pallor, and activity intolerance.
• Screen for severe-manifestation cues such as splenomegaly, jaundice, bone-change features, and progressive functional decline.
• Review CBC trends (Hb, RBC, Hct) and correlate with symptoms and current treatment intensity.
• Review hemoglobin electrophoresis interpretation, including elevated HbA2 and/or HbF patterns that support thalassemia diagnosis.
• Track iron studies and ferritin for transfusion-related iron overload risk.
• Review peripheral smear results for microcytic and hypochromic RBC patterns.
• Include genetic-testing and family-history review to support diagnosis confirmation and counseling.
• Assess adherence barriers, emotional burden, and family understanding of long-term disease management.

Nursing Interventions

• Coordinate and monitor scheduled transfusion care using strict verification and reaction surveillance workflows.
• Administer and monitor prescribed iron-chelation therapy; reinforce adherence and trend ferritin/iron markers over time.
• Support oxygenation and activity pacing when tissue-hypoxia symptoms worsen.
• Reinforce vaccination adherence, infection-prevention behaviors, and ongoing follow-up continuity.
• Administer folate supplementation as ordered to support RBC production.
• Provide patient and caregiver education on disease course, treatment options, and red-flag symptoms requiring escalation.
• Coordinate genetic-counseling referral for patients with thalassemia or thalassemia trait who are planning pregnancy.
• Evaluate outcomes against individualized targets, including symptom improvement and hemoglobin response (for example, sustained levels above 9 g/dL in selected treatment plans).

Iron Overload Progression

Repeated transfusions can cause organ-damaging iron accumulation unless chelation therapy and surveillance are maintained.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
iron-chelation-therapy	Class-based iron chelators	Monitor ferritin/iron trends, adverse effects, and long-term adherence.
Folate support	Folate supplementation	Supports erythropoiesis in chronic-anemia management plans.

Clinical Judgment Application

Clinical Scenario

A transfusion-dependent patient with beta-thalassemia reports worsening fatigue and dyspnea; CBC shows persistent anemia and ferritin is rising.

• Recognize Cues: Ongoing anemia symptoms with increasing iron-burden signal.
• Analyze Cues: Current transfusion benefit may be offset by untreated iron accumulation risk.
• Prioritize Hypotheses: Priority is balancing oxygen-carrying support with iron-overload prevention.
• Generate Solutions: Coordinate transfusion plan review, chelation optimization, and close lab monitoring.
• Take Action: Implement ordered therapies, monitor response, and reinforce adherence teaching.
• Evaluate Outcomes: Symptoms improve, hemoglobin stabilizes, and ferritin trend is controlled.

Related Concepts

• anemia-overview-and-transfusion-thresholds - Shared chronic-anemia assessment and oxygen-delivery framework.
• cbc - Core lab patterning for anemia severity and red-cell morphology trends.
• blood-transfusion-verification-initiation-and-reaction-response - Safety-critical transfusion workflow.
• sickle-cell-disease - Contrasting hereditary hemoglobinopathy with vaso-occlusive crisis predominance.
• bone-marrow-aspiration-and-biopsy-care - Procedural support when marrow production evaluation is needed.
• preconception-conditions-affecting-pregnancy - Family-planning and preconception risk optimization for hemoglobinopathy pathways.

Self-Check

1. Which findings suggest transition from mild thalassemia burden to high-acuity chronic-anemia management?
2. Why are ferritin and iron studies essential in transfusion-dependent thalassemia?
3. How does hemoglobin electrophoresis help differentiate thalassemia from other anemia causes?